LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on ATXS stock, giving a Buy rating on August 13.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sam Slutsky’s rating is based on several promising developments surrounding Astria Therapeutics. The company is actively enrolling patients in its pivotal Phase 3 ALPHA-ORBIT trial for navenibart, a long-acting plasma kallikrein inhibitor aimed at providing prophylactic treatment for hereditary angioedema (HAE). This trial positions Astria well in the competitive landscape, especially given the recent FDA approval of Ionis’ Dawnzera, which has limitations that navenibart could potentially address.
Additionally, Astria Therapeutics has a solid financial position, with over 2.5 years of cash runway and a manageable annual cash burn. This financial stability supports the company’s ongoing research and development efforts. Furthermore, the short interest in the company’s stock is relatively low, suggesting a positive market sentiment. These factors collectively contribute to Sam Slutsky’s Buy rating for Astria Therapeutics.
According to TipRanks, Slutsky is a 4-star analyst with an average return of 9.9% and a 37.89% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Abivax SA Sponsored ADR, Celldex, and DBV Technologies SA – American.
In another report released on August 13, TD Cowen also maintained a Buy rating on the stock with a $35.00 price target.